Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,618 recruiting studies in this area right now.
By phase
- Not applicable9,796
- Phase 24,454
- Phase 12,738
- Phase 1/Phase 21,689
- Phase 31,398
- Phase 2/Phase 3279
- Phase 4264
Top conditions
- Breast Cancer1,228
- Cancer662
- Prostate Cancer654
- Colorectal Cancer492
- Lung Cancer425
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer297
- Acute Myeloid Leukemia292
- Pancreatic Cancer292
- Hepatocellular Carcinoma283
- Solid Tumor257
- Advanced Solid Tumor256
- Cervical Cancer232
- Head and Neck Cancer228
- Endometrial Cancer207
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)285
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,428
- Texas639
- Arizona511
- Florida450
- Alabama419
- New York410
- Massachusetts342
- Maryland329
- New Jersey269
- Pennsylvania240
Recruiting studies20,618 total
- NCT07281768RecruitingPhase 2
Chemo and immunotherapy for locally advanced rectal cancer
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Baltimore, MarylandAges 18 years+ - NCT07219459RecruitingPhase 2
New drug combo for liver cancer after PD-1/PD-L1 treatment fails
This study tests three drugs (visugromab, nivolumab, lenvatinib) compared to a placebo plus lenvatinib for people with liver cancer (HCC) that cannot be removed or has spread, and who have already been treated with a PD-1/PD-L1 inhibitor without success. The goal is to see if the combination can help shrink tumors or slow the cancer.
Los Angeles, CaliforniaAges 18–100 - NCT06798363RecruitingPhase 2/Phase 3
Testing different doses of propranolol for ulcerated hemangioma in children.
This trial tests different starting doses of oral propranolol to see which works best and is safest for treating infantile hemangiomas that have ulcers (sores). It may help your child heal faster.
Chengdu, SichuanAges 1 month–4 years - NCT07253142RecruitingPhase 2
Study of HLX43 with Serplulimab for advanced lung cancer
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
Hefei, AnhuiAges 18–75 - NCT02595957Recruiting
Study about how people understand genetic test results
This trial studies what people and families think and understand about genetic test results, especially when results suggest a higher risk for disease. It may also include interviews and follow-up, and in some cases additional family testing if it fits the study’s goals.
Bethesda, MarylandAges 1 month–105 years - NCT07200089RecruitingPhase 1
IL-7 treatment after CAR-T therapy for multiple myeloma
This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.
St Louis, MissouriAges 18 years+ - NCT07707232Recruiting
Using AI to read PSMA PET/CT reports for prostate cancer
This trial uses a computer program (large language model) to help doctors read Chinese PSMA PET/CT reports. The goal is to see if the AI can accurately identify key details about prostate cancer, like where it has spread, which may help make staging and treatment decisions faster.
Wenzhou, ZhejiangAges 18 years+ - NCT06111781RecruitingPhase 2
Hormone Therapy and Radiation for Intermediate Risk Prostate Cancer
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
New Haven, ConnecticutAges 18 years+ - NCT04629677Recruiting
Portal vein stent for narrowed portal blood vessels
This trial looks at whether placing a small metal stent in the portal vein and nearby veins can improve problems caused by major narrowing (or clotting) of these vessels in people with gastrointestinal cancers. If you have significant vessel narrowing, the study may offer a targeted way to relieve pressure and symptoms that are not caused by the tumor directly.
Houston, TexasAges 18 years+ - NCT06039371RecruitingPhase 2
High dose testosterone during chemo for advanced prostate cancer
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
Seattle, WashingtonAges 18 years+ - NCT07234539Enrolling by invitation
AI tool for thyroid cancer management
This study tests an artificial intelligence (AI) helper that assists doctors in managing thyroid cancer. It aims to see if the tool can improve care for patients like you.
Hong KongAges 18 years+ - NCT07061652Recruiting
Support program for caregivers of patients with cancer and diabetes
This study supports family members or friends who care for someone with both cancer and diabetes. It tests a program to help caregivers manage their own stress and health while supporting their loved one.
Tampa, FloridaAges 18–99 - NCT06088771RecruitingPhase 1/Phase 2
Study of dupilumab and cemiplimab before lung cancer surgery
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT07438782RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07211737RecruitingPhase 1
C7R-GD2 CAR-T cells for osteosarcoma or neuroblastoma
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
Houston, TexasAges 1–24 - NCT07221825Recruiting
Radium-223 imaging study for men with prostate cancer
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
St Louis, MissouriAges 18 years+ - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Anchorage, AlaskaAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Orange, CaliforniaAges 18 years+ - NCT04722523RecruitingPhase 1
Cemiplimab plus chemo and other immune treatment for head and neck cancer
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
Basking Ridge, New JerseyAges 18 years+ - NCT07230613RecruitingPhase 2
Immunotherapy before surgery for localized melanoma
This trial tests if giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can improve outcomes for patients with stage III melanoma that can be removed. It is for people who have not had certain treatments recently or whose melanoma is not in the eye.
BordeauxAges 18 years+ - NCT07712848RecruitingPhase 3
Comparing 3 drug combos for newly diagnosed AML
This trial tests whether a new combination (DEC3-VEN) works better than two other standard treatments for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find the best initial therapy to help achieve remission.
Kunming, YunnanAges 18–65 - NCT05307705RecruitingPhase 1
Testing LOXO-783 for PIK3CA-mutated cancers
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06863402RecruitingPhase 2
Study of two drugs for Richter transformation lymphoma
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
Buffalo, New YorkAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,618 recruiting oncology studies from the U.S. registry right now, out of 31,344 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.